CG Oncology updates investor presentation for conference

CG Oncology, Inc. filed a current report to let investors know it plans to discuss an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025.

Accepted by SEC EDGAR 09/09/2025 - 07:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CG Oncology, Inc. filed a current report to let investors know it plans to discuss an updated corporate presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025. The presentation, dated the same day, is provided as Exhibit 99.1 and is incorporated by reference in the report.

The company emphasizes that the information in the presentation is being furnished under Regulation FD and is not considered "filed" for purposes of certain liability provisions under U.S. securities laws, unless specifically incorporated into other documents. CG Oncology also notes it has no obligation to update the presentation, though future updates may be made through additional SEC filings or other public disclosures.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CGON disclose in this 8-K filing?

CG Oncology, Inc. disclosed that it will discuss an updated Corporate Presentation at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025, and furnished the presentation as Exhibit 99.1.

What is Exhibit 99.1 in CGON's 8-K?

Exhibit 99.1 is CG Oncology, Inc.’s updated Corporate Presentation dated September 9, 2025, which the company intends to use at the Morgan Stanley Global Healthcare Conference.

Is the CGON corporate presentation considered "filed" with the SEC?

No. The company states that the information furnished under Item 7.01, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Exchange Act, unless specifically incorporated by reference into another filing.

Does CG Oncology have to update the corporate presentation after this 8-K?

CG Oncology, Inc. states it has no duty or obligation to publicly update or revise the Corporate Presentation, although it may do so through future SEC reports, press releases, or other public disclosures.

Why did CGON use Item 7.01 Regulation FD Disclosure?

Item 7.01 allows CG Oncology, Inc. to furnish information intended for broad, fair disclosure to the market, such as the updated Corporate Presentation used at an investor conference.

Who signed the CGON 8-K related to the corporate presentation?

The 8-K was signed on behalf of CG Oncology, Inc. by Josh Patterson, the company’s General Counsel and Chief Compliance Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

false000199179200019917922025-09-092025-09-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 09, 2025

CG Oncology, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41925	37-1611499
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
400 Spectrum Center Drive Suite 2040
Irvine, California				92618
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (949) 409-3700

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CGON		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

CG Oncology, Inc. (the “Company”) intends to discuss an updated corporate presentation (the “Corporate Presentation”) at the 23rd Annual Morgan Stanley Global Healthcare Conference on September 9, 2025. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Current Report”) and is incorporated by reference herein.

By furnishing the information in this Item 7.01 of this Current Report, including Exhibit 99.1, the Company makes no admission as to the materiality of such information. The information contained herein is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the Corporate Presentation, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

In accordance with General Instruction B.2 of Form 8-K, the information furnished with this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation dated September 9, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CG Oncology, Inc.
Date: September 9, 2025	By: /s/ Josh Patterson
	Name: Josh Patterson
	Title: General Counsel and Chief Compliance Officer